-
This week there were 2 articles in the New England Journal of Medicine that explored the link between postmenopausal hormone use and heart disease. The first article was the final analysis of the Prempro® arm of the WHI.
-
-
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.
-
There are arguments about the optimal treatment for ulcers with nonbleeding visible vessels and adherent clots. This study showed that the combination of endoscopic hemostasis with IV proton pump inhibitor therapy is superior to PPI alone in management of such patients.
-
Vardenafil has been approved for the treatment of erectile dysfunction in men. The drug is the second oral type 5 phosphodiestase (PDE5) inhibitor approved for this indication along with sildenafil (Viagra).
-
Insulin 70/30 Mix Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and Diabetes
-
Patients with unexplained chronic fatigue and bodily pain are more likely to have rhinosinusitis symptoms than are people in the general population.
-
Eighty-seven percent or more of patients with fatal or nonfatal myocardial infarction have major risk factors prior to the event.
-
Azithromycin is an effective, single-drug therapy for mild-to-moderate community-acquired pneumonia.
